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Abstract 25 
Heat and hypoxia exacerbate central nervous system (CNS) fatigue. We therefore investigated 26 
whether essential-amino-acid (EAA) and caffeine ingestion attenuates CNS fatigue in a 27 
simulated team-sport specific running protocol in a hot and hypoxic environment. 28 
Sub-elite male team-sport athletes (n=8) performed a repeat-sprint running protocol on a non-29 
motorized treadmill in an extreme environment on four separate occasions. Participants ingested 30 
one of four supplements: a double placebo, 3 mg.kg
-1
 body mass of caffeine+placebo, 2x7 g 31 
EAA (Musashi Create™)+placebo, or caffeine+EAA prior to each exercise session using a 32 
randomized, double-blind crossover design. Electromyography (EMG) activity and quadriceps 33 
evoked responses to magnetic stimulation were assessed from the dominant leg at pre-, half-time, 34 
and post-exercise. Central activation ratio (CAR) was used to quantify completeness of 35 
quadriceps activation. Oxygenation of the pre-frontal cortex was measured via near-infrared 36 
spectroscopy. Mean sprint work was higher (+174J, 23–24J; mean, 95% confidence interval, 37 
d=0.30; effect size, likely beneficial) in the caffeine+EAA condition versus EAAs alone, but not 38 
caffeine or a placebo. The decline in EMG activity was less (13%, 0–26%;  d=0.58, likely) in 39 
caffeine+EAA versus EAA alone.  Similarly, the pre-to-post exercise decrement in CAR was 40 
significantly less (-2.7%, 0.4–5.4%;  d=0.50, likely) when caffeine+EAA were ingested 41 
compared to placebo. Cerebral oxygenation was lower (-5.6%, 1.0–10.1%;  d=0.60, very likely) 42 
in the caffeine+EAA condition compared to LNAA alone. Co-ingestion of caffeine and EAA 43 
appears to maintain muscle activation and central drive, with a small improvement in running 44 
performance relative to EAA alone in hot, hypoxic environments.  45 
Key words – Repeated sprint exercise, Central fatigue, Hypoxia, Heat, Amino acids, Caffeine 46 
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Introduction 47 
Fatigue is characterized by the inability of skeletal muscle to maintain the required power output 48 
(Allen et al. 2008), and may occur at a muscular level (peripheral fatigue) or in the central 49 
nervous system (CNS, central fatigue). Central fatigue manifests as the inadequacy to voluntarily 50 
activate muscles (Gandevia 2001), alterations in cognitive function, perception of effort, and 51 
pain (Meeusen et al. 2006). The Central Governor theory highlights the importance of the CNS 52 
and the potential role of accumulation and/or depletion of neurotransmitters in fatigue (Noakes 53 
2011). Because neurotransmitter synthesis and function can be manipulated using nutritional 54 
strategies, it may be possible to use these strategies to reduce central fatigue (Pardridge 1998; 55 
Meeusen et al. 2006).  56 
 57 
Caffeine is considered a legitimate nutritional supplement in competitive sport to delay the onset 58 
of fatigue. Research on the impact of EAA on fatigue, however, has been equivocal (Davis et al. 59 
1999; Watson et al. 2004; Stepto et al. 2011). EAA supplementation did not improve 60 
performance in endurance exercise (Madsen et al. 1996; Davis et al. 1999)  in normal conditions 61 
(thermoneutral, normoxic environment), but may do so in the heat when production of dopamine 62 
is augmented. (Mittleman et al. 1998; Tumilty et al. 2011) Reducing dopamine synthesis is 63 
associated with a quicker onset of fatigue (Bailey et al. 1993). To our knowledge no studies have 64 
examined the effect of EAA supplementation on exercise performance in hypoxia.  65 
 66 
Caffeine may enhance performance in endurance exercise, (Doherty & Smith 2004; Ganio et al. 67 
2009), high-intensity running, and sprint activity (Glaister et al. 2008; Astorino & Roberson 68 
2010) in normal conditions. Caffeine ingestion prior to exercise can reduce ratings of perceived 69 
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exertion (RPE) (Doherty & Smith 2005), improve running power (Schneiker et al. 2006), and 70 
decrease sprint times (Glaister et al. 2008; Gant et al. 2010). Evidence for an ergogenic effect of 71 
caffeine in hypoxia is limited or equivocal when exercise is performed in the heat (Del Coso et 72 
al. 2008; Roelands et al. 2011).  73 
 74 
Exercise in the heat and/or at altitude represents a situation of maximal environmental stress that 75 
could accelerate the development of central fatigue. Voluntary muscle activation is reduced after 76 
exercise in the heat (Skein et al. 2012),  possibly related to altered dopamine activity and 77 
inhibitory signals from thermoreceptors in the hypothalamus (Nybo 2008). Similarly, voluntary 78 
activation is reduced after exercising in hypoxia (Verges et al. 2012; Billaut et al. 2013) as a 79 
result of cerebral deoxygenation (Smith & Billaut 2010; Billaut et al. 2013). Therefore, 80 
manipulating environmental conditions in combination with nutritional interventions can provide 81 
insights into novel supplementation strategies and the mechanisms of CNS fatigue. 82 
 83 
The aim of this study was to investigate whether nutritional supplementation can attenuate 84 
central fatigue and reduce performance decrements under conditions of environmental stress 85 
(simulated heat and hypoxia). Although these conditions are uncommon, it provides an 86 
opportunity to observe the potentially beneficial effects of nutritional manipulations under 87 
standardized conditions. Nutritional supplementation, in combination with assessing markers of 88 
central fatigue (e.g., muscle recruitment, central drive), will clarify the viability of invoking 89 
changes in neurotransmitter concentration in relation to central fatigue. We hypothesized that 90 
central fatigue and decrements in intermittent-exercise performance induced by environmental 91 
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stress would be attenuated by targeted nutritional supplementation strategies utilizing a 92 
combination of both caffeine and EAAs. 93 
 94 
Materials and Methods 95 
Participants  96 
Ten male, sub-elite football players regularly competing and training (~60 min, 3 times per 97 
week) volunteered for the study (Table 1). Two athletes were unable to complete the study, due 98 
to issues and/or injuries unrelated to the study. Prior to participation, each subject provided 99 
written informed consent for their voluntary participation in the study. The study was approved 100 
by the local Human Research Ethics Committee. 101 
 102 
Participant characterisation/familiarisation 103 
Participants reported to the laboratory 10-14 days prior to the experimental protocols on two 104 
occasions. On the first visit, age, height and body mass were recorded, body composition 105 
assessed by a whole body light scanner ([TC]
2
, Cary, U.S.A., (Ryder & Ball 2012)), and 106 
participants were familiarized with the exercise protocol. On the second visit, participants 107 
performed a 20-m sprint followed, 30 min later, by the Yo-Yo intermittent recovery test (Mohr et 108 
al. 2003).  109 
 110 
Diet and exercise control 111 
Two days prior to each experimental trial participants consumed a moderate-high carbohydrate 112 
diet (4 g.kg
-1
 body mass) that provided ~106 kJ.kg
-1
 body mass per day (70% CHO, 15% protein 113 
and 15% fat), while controlling protein intake in line with Australian dietary recommendations. 114 
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Participants were also instructed to abstain from any caffeinated products, alcohol and formal 115 
exercise training 24 h prior to testing. 116 
 117 
Study design 118 
In each session, after voiding, and being weighed, athletes consumed the initial supplement 119 
(EAA or Placebo) and remained in the laboratory at normoxic and thermoneutral conditions for 120 
the first 2 hours prior to exercise (Figure 1). At the end of this period, one hour before exercise, 121 
athletes consumed the second dose of supplements (caffeine, placebo and/or EAA) and rested in 122 
the environmental exercise laboratory (15% O2 [~2700m above sea level], 30
◦
C and 20% relative 123 
humidity). Although this combination of conditions is uncommon, in research studies it provides 124 
a unique opportunity to invoke central fatigue under standardized conditions and observe the 125 
potentially-beneficial effects of nutritional manipulations.  126 
 127 
Table 1: Participant characteristics 
Age 
Height (cm) 
Body mass (kg) 
Estimated body fat (%) 
20m sprint time (sec) 
Yo-Yo IR1 distance (m) 
Estimated VO2 max 
(ml/kg.min
-1
) 
22 ± 2 
181 ± 6 
77 ± 11 
14.7 ± 4.4 
3.1 ± 0.1 
1320 ± 528 
47.5 ± 4.4 
 128 
 129 
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130 
Figure 1: Schematic diagram of the study design. Supp = Supplement, Magstim = Central 131 
activation and MVC assessment, BW = Body Weight.  132 
 133 
Exercise Protocol 134 
The exercise protocol (Figure 2) was designed to mimic the running profile of team-sport 135 
athletes (Sirotic & Coutts 2008; Zois et al. 2013). During each session, participants completed a 136 
total of 6 sets of 4 s sprints with 8 s of rest between each sprint on a non-motorized treadmill 137 
(Woodway Force, Waukesha, U.S.A.). The time between each sprint set was interspersed with 138 
standing (22% of total time), walking (27%), jogging (22%), running (12%) and fast running 139 
(9%). Mean power, peak power and peak velocities during the exercise protocol were recorded 140 
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by the treadmill force transducer at 25 Hz. Performance data were stored and analyzed as 141 
described previously (Serpiello et al. 2011). 142 
 143 
Figure 2:  Graphical representation of one half of the exercise protocol, including 3 x 4 x 4 144 
second sprints and intermittent activity for participants with a maximal sprint speed of 4.8 – 5.2 145 
m.s
-1
. This protocol was completed twice with a 10 minute break in-between to simulate half-146 
time.  147 
 148 
Supplementation regimens 149 
Four supplement protocols were undertaken in a counterbalanced, randomized and double-blind 150 
fashion to provide the participants with a placebo, caffeine only, EAA only, or caffeine + EAA 151 
(Figure 1). The EAA was provided in two 7 g doses of Musashi Create
TM 
powder, dissolved in 152 
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250 ml of water containing; arginine (854 mg), leucine (837 mg), phenylalanine (794 mg), lysine 153 
(709 mg), valine (598 mg), histidine (555 mg), isoleucine (512 mg), threonine (418 mg) and 154 
methionine (162 mg), to reduce serotonin, and increase dopamine production within the CNS. 155 
Musashi also provided an inactive placebo that was indistinguishable in color and taste. 156 
Anecdotally, participants were unable to correctly identify any of the treatments. The EAAs or 157 
placebos were given to the participants 3 h and 1 h prior to commencing exercise trials. Caffeine 158 
(to block the action of adenosine; No-Doz
TM
; 3 mg.kg
.-1
 body mass) or placebo (CaCO3) was 159 
given to participants as a capsule (blinded) 1 h before exercise. Immediately before the warm-up, 160 
participants also consumed a carbohydrate gel (27 g; Powerbar Gel™, Musashi Performance 161 
Nutrition, Nestle, Australia) to ensure adequate provision of carbohydrate (Figure 1). 162 
 163 
Blood sampling 164 
Six 5ml blood samples were taken at regular intervals in each trial (Figure 1).  Baseline blood 165 
samples (3 h pre-) were taken prior to the ingestion of the initial supplement. Blood samples 166 
were analyzed immediately for partial pressure of oxygen (pO2), partial pressure of carbon 167 
dioxide (pCO2), oxygen saturation (sO2) (Siemens, Henkestrasse, Germany) and lactate and 168 
glucose concentrations (YSI, Yellow Springs, U.S.A). 169 
 170 
Central fatigue assessment  171 
The knee extension protocol used has been described in detail elsewhere (Billaut et al. 2013). 172 
Before, at half-time, and immediately after exercise, participants were instructed to perform a 173 
maximum voluntary contraction (MVC) of the quadriceps (dominant leg) against the strain 174 
gauge. In this position, a magnetic stimulator (Magstim RAPID; JLM Accutek Healthcare,  175 
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NSW) and a double 70-mm coil (producing two overlapping circular fields) were used to 176 
stimulate each participant’s quadriceps during the MVC (Amann et al. 2007; Billaut et al. 2013). 177 
The central activation ratio (CAR) was calculated as described previously, where 178 
CAR=MVC/(MVC + superimposed twitch) (Gandevia 2001).  179 
 180 
Surface electromyography (EMG) acquisition and analysis 181 
EMG signals were recorded via skin surface electrodes over the vastus lateralis, rectus femoris, 182 
tibialis anterior, biceps femoris, gluteus maximus and lateral gastrocnemius of the dominant 183 
lower limb. In each trial, electrodes were secured to the skin with tape and an elastic tubing to 184 
prevent cable movements.  In the first trial, electrode placement was marked with a permanent 185 
marker to ensure that the position of the electrodes was replicated on subsequent visits.  186 
EMG signals were collected using the Delsys system (Delsys Inc., Boston, MA) at 2 kHz after 187 
being filtered with a 50-Hz line filter. Muscle activity was quantified as the integrated EMG of 188 
the signal between the onset and offset of activation of each burst in the last 2 s of every 4 s 189 
sprint. EMG signal from all muscles were added together to provide a value representative of 190 
overall muscle activation in the lower limb. Data were normalized to the first sprint set to 191 
provide a percentage change for total electrical activity to account for a potential 192 
disproportionate effect of the first sprint.  193 
 194 
Near-Infrared Spectroscopy (NIRS) measurement and analysis  195 
Brain oxygenation was measured using NIRS (Artinis Medical Systems, AS Zetten, 196 
Netherlands). The protocol allowed the calculation of the tissue saturation index (TSI) for 197 
cerebral tissue (Smith & Billaut 2010; Billaut et al. 2013). 198 
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Plasma amino acid analysis 199 
Concentrations of the free amino acids histidine, arginine, threonine, lysine, methionine, valine, 200 
isoleucine, leucine, phenylalanine, and tryptophanin in plasma were determined using reversed-201 
phase high-performance liquid chromatography (RP-HPLC) as previously reported (Stepto et al. 202 
2011). The limit of quantitation for this study was 0.5μmol.L–1 with intra- and inter-assay 203 
variability of 4.5% and 5.1%, respectively, for tryptophan, and <2.3% and 3.8%, respectively, for 204 
the other EAAs.  205 
 206 
Caffeine analysis 207 
Plasma caffeine concentrations were assessed via RP-HPLC (GBC Scientific HPLC system, 208 
GBC Scientific, Victoria, Australia) according to the method of Alvi & Hammami (2011). The 209 
internal standard was antipyrine in 30% HClO4 [40 µg/ml]) A 5µm, 4.6x150mm RP C18 column 210 
and a 5µm, 4.6x20mm Guard Cartridge insert (Water Atlantis
®
 T3) were used for the separation. 211 
The mobile phase consisted of 15 mM potassium phosphate (pH 3.5) and acetonitrile (83:17, 212 
v/v), The analysis was performed under isocratic conditions using a flow rate of 1.0 mL.min
-1
. 213 
Chromatograms were recorded at 274 nm with a run time of 10 min. The data were collected 214 
with a personal computer using EZChrom Elite Chromatography Manager Software and plasma 215 
caffeine concentration determined using peak area ratio (caffeine to antipyrine). The assays limit 216 
of quantification in plasma was 0.05 mg.L
-1
 with an intra- and inter- assay variability of 2.5% 217 
and 5.6% respectively.  218 
 219 
 220 
 221 
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Statistical analysis 222 
Data for the 8 participants are expressed as mean ± SD (see Supplementary Tables 1-4). All data 223 
were analyzed using a linear mixed model of the estimated true difference between 224 
supplementation protocols with Bonferroni post hoc adjustments used where appropriate. 225 
Estimated mean differences for the fixed effects of time and supplementation strategy, and the 226 
interaction of both (time  supplement) were determined for each parameter. Precision of 227 
estimation was indicated with 95% confidence intervals (95%CI). Magnitudes of difference 228 
between treatments were determined using the standardized mean difference (effect size), the 229 
within-subject placebo standard deviation, and are expressed as Cohen’s d.  Chances of the true 230 
value of the effect being possibly (≥75%), likely (≥95%), very likely (≥99.5%), or most likely 231 
(=100%), were calculated according to established criteria (Hopkins et al. 2009), with clinical 232 
chances of benefit or harm considered for running performance variables. An n=8 subjects 233 
provided adequate statistical power in a post-only cross-over design assuming a reference 234 
difference (between treatments) in work done of 7%, a typical error in repeat sprints of 4.5%, 235 
and Type I and II errors of 5% and 20% respectively. 236 
 237 
Results 238 
Running performance: Participants ingesting a combination of caffeine + EAAs completed 239 
more mean sprint work (+174 J, 23–324 J; mean difference, 95%CI; d=0.30, likely beneficial ; 240 
Table 2) and mean sprint power (43 W, 6–81 W; d=0.30, likely beneficial), and had higher peak 241 
sprint velocity (0.17 m.s
-1
, 0.04–0.31 m.s-1; d=0.50, very likely beneficial) compared to EAA’s 242 
alone (Table 2). Mean sprint work, power and velocity were greater in set 1 compared to all 243 
other sets (Supplementary Table 1). There was no interaction effect between time and 244 
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supplement for any running performance variables. Total work performed excluding the sprints 245 
showed no significant differences between supplementation protocols.  246 
 247 
Table 2: Comparison of mechanical data between supplementation strategies. Data are mean ± SD 
 Placebo Caffeine LNAA Caffeine + LNAA 
Mean Sprint Work (J) 2705 ± 581 2791 ± 604 2678 ± 664 2858 ± 763* 
Mean Sprint Power (W) 676 ± 145 698 ± 151 669 ± 166 715 ± 191* 
Peak Sprint Velocity (m.s-1) 5.78 ± 0.34 5.83 ± 0.35 5.76 ± 0.44 5.94 ± 0.37* 
Total Work (Without Sprints) (J) 104894 ± 18359 108638 ± 15593 105047 ± 14985 103086 ± 18698 
* denotes statistical significant difference from LNAA where p ≤ 0.05 
 248 
Blood parameters: All supplementation strategies were effective in elevating protein and 249 
caffeine concentration (Figure 3, Supplementary table 2).  250 
 251 
EAA: In particular, supplementing with EAAs reduced the plasma free tryptophan:LNAA ratio 252 
in the caffeine + EAA condition compared to placebo (0.0009, 0.0005–0.0013;d=0.76, most 253 
likely) and caffeine alone (0.0014, 0.0010–0.0018; d=1.21, most likely). There was an effect of 254 
time on the plasma free tryptophan:LNAA ratio consistent with ingestion timing.  255 
 256 
Caffeine: As expected, plasma caffeine was increased in the caffeine only condition when 257 
compared to placebo (4.3 µmol.L
-1
, 3.2–5.4 µmol.L-1; d=2.65, most likely), and EAA only (4.4 258 
µmol.L
-1
, 3.4–5.5 µmol.L-1; d=2.74, most likely). Plasma caffeine was also higher in the caffeine 259 
+ EAA condition compared to placebo (4.7 µmol.L
-1
, 3.6–5.7 µmol.L-1; d=2.88, most likely) and 260 
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EAA alone (4.8 µmol.L
-1
, 3.7-5.9 µmol.L
-1
; d=2.97, most likely; Figure 3B)  There was also an 261 
effect of time on caffeine concentration, relevant to when caffeine was ingested.  262 
 263 
pO2 & SO2: Venous blood pO2 was substantially higher in the caffeine + EAA treatment 264 
compared to caffeine alone (7.0 mmHg, 1.7–12.3mmHg; d=0.39, likely) and placebo (6.2 265 
mmHg, 1.1–11.2 mmHg; 0.35, likely) across the exercise protocol (Supplementary Table 2). 266 
Oxygen saturation, as indicated by venous blood SO2, increased from pre- to post-exercise by 267 
37% (23-50%; d=2.28, most likely) across treatments (Supplementary Table 2).  268 
 269 
Lactate: Blood lactate was also substantially higher (0.55 mmol L
-1
, 0.15–0.95;  d=0.17, 270 
possibly; Supplementary Table 2) in the caffeine + EAA group compared to a placebo across all 271 
time points.  272 
 273 
 274 
 275 
 276 
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 277 
Figure 3: Comparison of Free Tryptophan:LNAA ratio and caffeine concentrations between 278 
supplementation strategies. Data are estimated mean ± 95% CI. * denotes significant difference 279 
from EAA at time point where  p ≤ 0.05. + denotes significant difference from placebo at time 280 
point where p ≤ 0.05. ^ denotes significant difference from EAA overall where  p ≤ 0.05. # 281 
denotes significant difference from placebo overall where p ≤ 0.05.    indicates supplement 282 
ingestion time. 283 
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MVC: Overall, MVC force was higher (31nM, 8–54nM; d=0.62, likely beneficial) when caffeine 284 
+ EAA were ingested compared to a placebo (Figure 4A).  285 
 286 
Peripheral Twitch: Peripheral twitch force was not different between supplementation protocols 287 
across all time points. 288 
 289 
Central Activation Ratio and EMG: The decline in normalized EMG activity was attenuated 290 
with caffeine + EAA compared with placebo (19%, 9–29%; d=0.84, most likely beneficial) and 291 
EAA alone (13%, 0–26%; d=0.58, likely beneficial). Supplementing with ‘caffeine only’ 292 
resulted in a lower reduction in normalized EMG compared to placebo (15%, 1–29%; d=0.67, 293 
likely beneficial; Figure 4B). There was no effect of time and no interaction between time and 294 
supplement for decline in EMG activity (Supplementary Table 1). Ingesting a combination of 295 
caffeine + EAA resulted in a higher overall CAR (2.7%, -5.4 to -0.4%; d=0.5, likely beneficial; 296 
Figure 4C) compared to a placebo. There was no effect of time, and no interaction between time 297 
and supplement. 298 
 299 
NIRS: Greater mean declines in TSI across the exercise protocol were observed when caffeine (-300 
8.3%, 3.7–13.0%; d=0.9, most likely beneficial) and caffeine + EAA (-5.6%, 1.0–10.1%; d=0.6, 301 
very likely beneficial) were ingested (the two conditions that produced the highest amount of 302 
work), compared with EAAs alone (Figure 4D, Supplementary Table 1).  303 
 304 
 305 
 306 
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 307 
 308 
Figure 4: Comparison of central fatigue markers and total work (J) between supplementation 309 
strategies.  Data are estimated mean ± 95%CI. * denotes significant difference from EAA at time 310 
point where p ≤ 0.05. + denotes significant difference from placebo at time point where p ≤ 0.05. 311 
^ denotes significant difference from EAA overall where  p ≤ 0.05. # denotes significant 312 
difference from placebo overall where p ≤ 0.05.  313 
 314 
 315 
 316 
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Discussion 317 
This study demonstrated, for the first time, that nutritional supplementation with a combination 318 
of caffeine and EAAs attenuated the development of central fatigue in response to simulated 319 
team-sport exercise in hot and hypoxic environmental conditions. Using EMG activity and CAR 320 
as markers of muscle recruitment and central activation, respectively, supplementation with 321 
caffeine + EAA delayed the onset of central fatigue in team-sport players, but this effect did not 322 
translate into clear performance benefits.  323 
 324 
Our supplementation protocol was designed to target two different neurotransmitter pathways to 325 
reduce central fatigue, based on previous literature (Pardridge 1998). Due to the challenges of 326 
measuring neurotransmitter concentrations in vivo in humans, we can only use a conceptual 327 
framework based on prior literature using EAA’s containing LNAA’s to manipulate 328 
neurotransmitters (Pardridge 1998). Our supplementation protocol used EAA’s (including 329 
LNAA’s) to inhibit serotonin synthesis as indicated by a lower free tryptophan:LNAA ratio 330 
(Figure 4A; (Pardridge 1998).  Additionally, we aimed to  promoting dopamine production  in 331 
the CNS via phenylalanine ingestion (Pardridge 1998). We believe this was achieved, as 332 
indicated by the lower ratio of free tryptophan:LNAA and increased phenylalanine 333 
concentrations in the plasma when EAAs were ingested with or without caffeine (Figure 4A, 334 
Supplementary Table 3). We believe this effectively lowered the serotonin:dopamine ratio, 335 
which is considered important in attenuating central fatigue (Fernstrom 2013). Secondly, we 336 
aimed to antagonise adenosine receptors via caffeine supplementation (Figure 4, Supplementary 337 
Table 3). Isolated EAA and caffeine supplementation are known to effect central drive and motor 338 
unit recruitment in thermoneutral (Meeusen et al. 2006) and hot environments (Del Coso et al. 339 
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2008; Meeusen & Roelands 2010). Antagonizing adenosine or increasing dopamine synthesis 340 
has been linked to maintenance of motor unit recruitment and frequency of activation concurrent 341 
with improved exercise performance (Del Coso et al. 2008). It is surprising that only caffeine 342 
and caffeine + EAA had a clear influence on central fatigue variables. We consider that changes 343 
in markers of central drive (CAR and EMG) are likely due to caffeine, and a minor contribution 344 
from the EAA’s in our combined supplementation protocol.  345 
 346 
Physiological changes in central fatigue variables induced by caffeine and/or EAA, did not 347 
translate into a substantial performance benefit. Participants who ingested a combination of 348 
caffeine and EAAs performed more work during sprints than with EAA alone, but not 349 
significantly more than with a placebo. This is surprising given that supplementation with 3–350 
6mg.kg
-1 
of caffeine has previously shown to improve sprint times and repeated-sprint 351 
performance (Glaister et al. 2008; Gant et al. 2010) compared to a placebo. While EAA 352 
supplementation may not improve performance in normal conditions, there is evidence it is 353 
beneficial when exercise is performed in the heat (Mittleman et al. 1998; Tumilty et al. 2011). 354 
However, the effect of EAA supplementation on high-intensity exercise performance is 355 
unknown. Our findings provide new insight into the influence of isolated and combined 356 
supplementation protocols on repeat-sprint performance.  357 
 358 
Cerebral oxygenation impairs central drive and motor unit recruitment during repeated-sprint 359 
performance in hypoxic conditions (Smith & Billaut 2010; Billaut et al. 2013), and other forms 360 
of high-intensity exercise (Rooks et al. 2010). Caffeine ingestion may reduce cerebral blood flow 361 
and oxygen availability (Kennedy & Haskell 2011), which could explain the observed reductions 362 
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in cerebral oxygenation in the final sets of sprints. However, our data appear to dissociate 363 
cerebral oxygenation as a mechanism for central fatigue in hot and hypoxic conditions. We 364 
consider that reduced cerebral oxygenation observed in the caffeine only and caffeine + EAA 365 
trials is a likely consequence of caffeine ingestion and/or the somewhat greater mechanical work 366 
produced.  367 
 368 
To our knowledge, this is the first study to measure central fatigue via EMG and magnetic 369 
stimulation in conjunction with nutritional supplementation. Although we used a simulated 370 
exercise protocol and unique environmental conditions, we believe our data provide novel 371 
insights into central fatigue and match performance. This study highlights the potential for 372 
nutritional interventions to sustain or enhance exercise performance in challenging 373 
environmental conditions. We observed large standard deviations in our performance data, which 374 
may be responsible for the lack of significant difference between caffeine + EAA and placebo 375 
supplementation protocols. Furthermore, the dose of caffeine used in the study is at the bottom of 376 
the recommended range for ergogenic benefit, which may explain why we observed no 377 
performance improvements with caffeine supplementation alone. We acknowledge that there 378 
may also have been an unaccounted for interaction between pre-exercise carbohydrate feeding 379 
and AA supplement on performance. Finally, it is plausible that the environmental conditions 380 
chosen for the study induced a level of fatigue that was too great for supplementation alone to 381 
overcome, again contributing to the lack of running performance improvements. The observed 382 
changes in central fatigue variables may have been too small to enhance performance and these 383 
relationships warrant further investigation.  384 
 385 
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In conclusion, team-sport athletes who ingest a combination of caffeine and EAA may attenuate 386 
central fatigue and perform more work than when ingesting EAA’s alone during repeated sprint 387 
exercise in hot, hypoxic conditions. The mechanisms explaining this improved performance 388 
appear to be associated with central drive and muscle activation, and, possibly, altered 389 
neurotransmitter production or function influencing the motivation to exercise. Further work 390 
should evaluate similar supplementation and exercise protocols in thermoneutral and normoxic 391 
conditions. This line of investigation would help establish the effectiveness of combining 392 
supplements for team-sport athletes in more common match and training environments. 393 
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Supplementary Table 1. Individual time point data for performance outcome variables (6 time points) Data are mean ± SD 
Variable Condition Set 1 Set 2 Set 3 Set 4 Set 5 Set 6 
Mean sprint work 
(J) 
 
Placebo 2860 ± 458 2719 ± 466 2510 ± 766 2819 ± 567 2599 ± 638 2722 ± 657 
Caffeine 2940 ± 484 2775 ± 687 2829 ± 664 2811 ± 610 2686 ± 671 2708 ± 660 
LNAA 2911 ± 530 2620 ± 798 2513 ± 826 2820 ± 595 2525 ± 680 2679 ± 634 
Caffeine + LNAA 2974 ± 677 2888 ± 860 2837 ± 814 2858 ± 781 2742 ± 821 2867 ± 868 
Mean sprint power 
(W) 
 
Placebo 715 ± 115 680 ± 117 628 ± 191 705 ± 142 650 ± 159 681 ± 164 
Caffeine 735 ± 121 694 ± 172 707 ± 166 703 ± 152 672 ± 167 677 ± 165 
LNAA 728 ±  132 655 ± 199 628 ± 206 705 ± 149 631 ± 170 670 ± 158 
Caffeine + LNAA 743 ± 169 722 ± 215 709 ± 203 715 ± 195 686 ± 205 717 ± 217 
Peak sprint 
velocity 
(m.s
-1
) 
 
Placebo 5.71 ± 0.35 5.78 ± 0.29 5.79 ± 0.41 5.74 ± 0.35 5.69 ± 0.40 5.97 ± 0.34 
Caffeine 5.81 ± 0.26 5.77 ± 0.32 6.00 ± 0.30 5.64 ± 0.44 5.75 ± 0.39 6.02 ± 0.29 
LNAA 5.79 ± 0.32 5.73 ± 0.47 5.79 ± 0.50 5.68 ± 0.47 5.63 ± 0.50 5.92 ± 0.45 
Caffeine + LNAA 5.93 ± 0.29 5.91 ± 0.30 6.00 ± 0.39 5.79 ± 0.30 5.87 ± 0.44 6.13 ± 0.46 
Mean EMG 
decline (%) 
 
Placebo 100 ± 0 31.5 ± 31.1 26.5 ± 9.2 26.7 ± 21.4 30.0 ± 17.7 38.2 ± 30.2 
Caffeine 100 ± 0 9.9 ± 9.7 20.9 ± 6.6    
LNAA 100 ± 0 25.2 ± 7.1 27.7 ± 4.3 11.8 ± 9.1 28.6 ± 4.0 30.2 ± 10.2 
Caffeine + LNAA 100 ± 0 4.9 ± 4.9 11.8 ± 5.8 15.4 ± 10.5 17.0 ± 8.5 11.9 ± 10.4 
Tissue saturation 
index (%) 
 
Placebo 66.8 ± 6.2 51.5 ± 4.9 55.6 ± 9.2 65.8 ± 7.1 60.2 ± 9.2 61.5 ± 9.8 
Caffeine 62.4 ± 9.3 49.1 ± 10.8 49.8 ± 11.8 56.4 ± 9.7 56.5 ± 10.5 53.2 ± 14.5 
LNAA 70.7 ± 8.3 58.1 ± 10.0 60.2 ± 9.3 67.9 ± 6.9 60.2 ± 9.4 60.8 ± 9.6 
Caffeine + LNAA 65.6 ± 9.5 46.7 ± 12.7 52.4 ± 7.9 62.3 ± 11.5 60.8 ± 16.9 57.1 ± 11.6 
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 Supplementary Table 2. Venous pCO2, pO2, sO2, lactate, and glucose concentrations between supplementation strategies. Data are mean ± 
SD 
Variable Condition 3hr pre 2hr pre 1hr pre Pre Half time Post 
pCO2 (mmHg) Placebo 57 ± 7 59 ± 4  62 ± 5 54 ± 9 33 ± 4 30 ± 5 
Caffeine 53 ± 9 55 ± 9 60 ± 5 56 ± 9 32 ± 7 30 ± 6 
LNAA 56 ± 7 57 ± 5 59 ± 4 50 ± 7 31 ± 6 31 ± 6 
Caffeine + LNAA* 59 ± 8 56 ± 8 57 ± 9 51 ± 8 28 ± 4 26 ± 3 
pO2 (mmHg) Placebo 31 ± 4 24 ± 3  20 ± 4 27 ± 10 53 ± 14 63 ± 9 
Caffeine 34 ± 8 27 ± 12 20 ± 4 24 ± 8 55 ± 17 54 ± 17 
LNAA 33 ± 11 24 ± 4 20 ± 4 33 ± 9 64 ± 13 60 ± 10 
Caffeine + LNAA*^ 33 ± 9 29 ± 8 24 ± 9 30 ± 10 65 ± 4 71 ± 3 
sO2 (%) Placebo 52 ± 11 39 ± 10 34 ± 12 46 ± 23 82 ± 12 89 ± 8 
Caffeine 65 ± 18 45 ± 23 31 ± 10 43 ± 19 80 ± 16 79 ± 16 
LNAA 58 ± 20 40 ± 12 30 ± 12 60 ± 19 88 ± 10 87 ± 8 
Caffeine + LNAA*^ 60 ± 13 51 ± 17 41 ± 20 53 ± 21 90 ± 1 92 ± 1 
Lactate 
(mmol/L) 
Placebo 0.9 ± 0.2 0.8  ± 0.2 0.8 ± 0.2 0.9 ± 0.1 7.1 ± 1.9 7.3 ± 1.9 
Caffeine 1.1 ± 0.5 0.9  ± 0.3 0.8 ± 0.2 1.0 ± 0.3 7.4 ± 2.0 8.5 ± 1.8 
LNAA 1.2 ± 0.7 0.9 ± 0.3 0.9 ± 0.6 1.2 ± 0.5 7.5 ± 1.9 7.1 ± 1.5 
Caffeine + LNAA* 0.9 ± 0.3 0.8 ± 0.1 0.9 ± 0.5 1.3 ± 0.9 8.2 ± 2.4 9.4 ± 2.4 
Glucose 
(mmol/L) 
Placebo 4.0 ± 0.9 4.1 ± 0.6 4.0 ± 0.4 4.7 ± 0.8 5.9 ± 0.9 5.6 ± 1.7 
Caffeine 4.5 ± 0.5 4.5 ± 0.8 4.5 ± 1.1 4.6 ± 0.7 6.1 ± 1.9 6.8 ± 1.8 
LNAA^ 4.5 ± 1.0 3.7 ± 0.3 4.4 ± 0.8 4.3 ± 0.5 6.3 ± 1.5 5.7 ± 1.3 
Caffeine + LNAA 3.9 ± 1.0 3.7 ± 0.3 4.2 ± 1.1 4.6 ± 0.9 6.8 ± 2.2 6.3 ± 1.8 
* denotes significant difference from placebo treatment over all time points where p ≤ 0.05 
^ denotes significant difference from caffeine treatment over all time points where p ≤ 0.05 
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Supplementary Table 3. Change in individual LNAA concentrations between supplementation strategies. Data are mean ± SD 
Variable Condition 3hr pre 2hr pre 1hr pre Pre Half time Post 
Histidine (µmol/L) 
 
Placebo*^ 82 ± 6 78 ± 6 78 ± 5 75 ± 8 82 ± 10 77 ±112 
Caffeine 80 ± 5 83 ± 7 81 ± 9 76 ± 10 77 ± 10 85 ± 9 
LNAA# 80 ± 9 104 ± 11 84 ± 9 109 ± 21 87 ± 9 85 ± 7 
Caffeine + LNAA 84 ± 12 119 ± 23 90 ± 11 116 ± 17 94 ± 14 91 ± 13 
Arginine (µmol/L) 
 
Placebo* 92 ± 9 84 ± 11 84 ± 9 76 ± 11 83 ± 15 81 ± 19 
Caffeine* 91 ± 14 90 ± 14 87 ± 13 77 ± 11 74 ± 12 82 ± 11 
LNAA 90 ± 19 124 ± 18 105 ± 14 139 ± 39 103 ± 15 96 ± 16 
Caffeine + LNAA 95 ± 16 145 ± 24 110 ± 11 138 ± 23 105 ± 9 91 ± 6 
Threonine 
(µmol/L) 
 
Placebo*^ 129 ± 23 122 ± 22 116 ± 15 108 ± 18 110 ± 17 105 ± 24 
Caffeine*^ 132 ± 29 131 ± 26 126 ± 22 116 ± 28 105 ± 20 115 ± 25 
LNAA 128 ± 32 141 ± 23 125 ± 19 153 ± 37 122 ± 18 121 ± 15 
Caffeine + LNAA* 136 ± 22 163 ± 24 137 ± 17 157 ± 32 129 ± 20 122 ± 16 
Lysine (µmol/L) 
 
Placebo*^ 167 ± 26 151 ± 21 146 ± 17 134 ± 22 147 ± 22 132 ± 27 
Caffeine*^ 170 ± 40 166 ± 30 158 ± 27 139 ± 33 126 ± 20 136 ± 16 
LNAA* 165 ± 51 196 ± 36 165 ± 31 200 ± 52 150 ± 28 136 ± 24 
Caffeine + LNAA 178 ± 48 238 ± 57 179 ± 22 211 ± 40 159 ± 24 143 ± 22 
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Methionine 
(µmol/L) 
 
Placebo* 28 ± 6 25 ± 5 23 ± 4 22 ± 4 24 ± 4 26 ± 6 
Caffeine 32 ± 6 29 ± 4 27 ± 4 24 ± 6 24 ± 5 28 ± 4 
LNAA 28 ± 7 34 ± 6 28 ± 4 34 ± 10 28 ± 4 28 ± 4 
Caffeine + LNAA 32 ± 7 40 ± 7 28 ± 5 34 ± 8 28 ± 5 27 ± 3 
Valine (µmol/L) 
 
Placebo*^ 255 ± 33 249 ± 62 241 ± 46 237 ± 33 240 ± 36 237 ± 49 
Caffeine*^ 257 ± 25 245 ± 28 240 ± 44 220 ± 21 211 ± 26 224 ± 43 
LNAA* 250 ± 46 320 ± 41 284 ± 22 372 ± 72 305 ± 40 285 ± 36 
Caffeine + LNAA 280 ± 45 391 ± 67 320 ± 50 402 ± 47 324 ± 38 301 ± 47 
Isoleucine 
(µmol/L) 
 
Placebo*^ 65 ± 15 60 ± 25 58 ± 17 62 ± 11 62 ± 14 65 ± 24 
Caffeine*^ 72 ± 13 62 ± 12 63 ± 21 55 ± 10 55 ± 8 61 ± 12 
LNAA 65 ± 17 100 ± 17 82 ± 19 122 ± 30 87 ± 14 77 ± 20 
Caffeine + LNAA 78 ± 15 125 ± 32 87 ± 24 121 ± 24 89 ± 21 69 ± 20 
Leucine (µmol/L) 
 
Placebo*^ 129 ± 23 118 ± 34 113 ± 25 116 ± 17 118 ± 19 120 ± 37 
Caffeine*^ 140 ± 25 125 ± 21 123 ± 35 108 ± 18 106 ± 13 116 ± 22 
LNAA 126 ± 29 179 ± 25 151 ± 25 213 ± 50 160 ± 23 142 ± 29 
Caffeine + LNAA 148 ± 8 222 ± 52 162 ± 38 220 ± 38 161 ± 27 136 ± 33 
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Phenylalanine 
(µmol/L) 
 
Placebo*^ 57 ± 7 52 ± 7 51 ± 8 52 ± 7 55 ± 7 57 ± 10 
Caffeine*^ 60 ± 10 58 ± 9 55 ± 10 52 ± 7 54 ± 6 60 ± 9 
LNAA* 55 ± 11 81 ± 14 73 ± 15 102 ± 23 88 ± 18 86 ± 12 
Caffeine + LNAA 62 ± 13 99 ± 24 75 ± 4 112 ± 22 96 ± 18 93 ± 14 
Tryptophan 
(µmol/L) 
 
Placebo^+ 4.0 ± 0.7 3.8 ± 0.8 3.6 ± 0.8 3.9 ± 0.6 5.1 ± 1.8 5.4 ± 1.0 
Caffeine^ 4.6 ± 0.4 4.2 ± 0.7 4.0 ± 1.0 3.9 ± 0.4 5.5 ± 1.2 6.2 ± 0.8 
LNAA* 4.3 ± 0.7 3.6 ± 0.5 3.4 ± 0.9 3.3 ± 1.1 4.2 ± 1.1 4.8 ± 1.2 
Caffeine + LNAA* 4.9 ± 0.8 4.3 ± 0.8 3.9 ± 0.7 4.1 ± 1.4 4.9 ± 0.8 5.2 ± 0.8 
* denotes significant difference between treatment and caffeine + LNAA treatment over all time points where p ≤ 0.05 
^ denotes significant difference between treatment and LNAA treatment over all time points where p ≤ 0.05 
+ denotes significant difference between treatment and caffeine treatment over all time points where p ≤ 0.05 
# denotes significant difference between treatment and placebo treatment over all time points where p ≤ 0.05 
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Supplementary Table 4. Individual time point data (3 time points) for main outcome variables. Data 
are mean ± SD 
Variable Condition Pre Half-Time Post 
Mean MVC force 
(nM) 
 
Placebo 211 ± 52 188 ± 48 195 ± 53 
Caffeine 218 ± 43 213 ± 44 226 ± 62 
LNAA 212 ± 46 204 ± 36 216 ± 40 
Caffeine + LNAA 215 ± 35 223 ± 41 231 ± 33 
Mean twitch force 
(nM) 
 
Placebo 68.5 ± 21.6 62.7 ± 22.9 71.2 ± 24.5 
Caffeine 68.1 ± 19.3 65.8 ± 22.9 69.5 ± 15.6 
LNAA 68.9 ± 20.9 65.0 ± 17.5 66.1 ± 14.5 
Caffeine + LNAA 62.8 ± 17.4 59.5 ± 12.2 71.0 ± 16.3 
Central activation 
ratio 
(%) 
 
Placebo 92.6 ± 2.9 91.1 ± 5.3 90.7 ± 7.6 
Caffeine 93.5 ± 1.5 92.5 ± 2.5 92.3 ± 5.5 
LNAA 92.9 ± 4.2 92.5 ± 4.7 92.9 ± 4.5 
Caffeine + LNAA 94.5 ± 2.0 93.9 ± 3.8 96.1 ± 2.2 
